@article{f0a6384376c54b58a292fa5fe1b5498b,
title = "Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS",
abstract = "Background: Optimizing multiple sclerosis treatment warrants understanding of changes in physical, mental, and social health. Objective: To assess the impact of natalizumab on Quality of Life in Neurological Disorders (Neuro-QoL) scores. Methods: Annualized change in T-scores and likelihood of ≥5-point improvement over baseline were calculated for each Neuro-QoL domain after natalizumab initiation. Comparisons with ocrelizumab-treated patients were conducted after propensity score weighting and adjustment for relevant co-medications, year, and drug-year interaction. Results: Among 164 natalizumab patients analyzed, 8 of 12 Neuro-QoL domains improved significantly, with greater improvement in patients with abnormal baseline Neuro-QoL. In the subgroup comparison of natalizumab-treated (n = 145) and ocrelizumab-treated (n = 520) patients, significant improvement occurred in 9 of 12 and 4 of 12 domains, respectively. The difference between groups was statistically significant for positive affect and well-being (p = 0.02), sleep (p = 0.003), and satisfaction with social roles and activities (SRA) (p = 0.03) in the overall population and for emotional and behavioral dyscontrol (p = 0.01), participation in SRA (p = 0.0001), and satisfaction with SRA (p = 0.02) in patients with abnormal baseline Neuro-QoL. Conclusions: Natalizumab can produce clinically meaningful improvements in mental and social health. Such improvements are unlikely to be primarily driven by expectation bias, as their magnitude exceeded improvements with another high-efficacy therapy, ocrelizumab.",
keywords = "Natalizumab, Neuro-QoL, depression, fatigue, multiple sclerosis, sleep",
author = "Hersh, {Carrie M.} and Bernd Kieseier and Moor, {Carl de} and Miller, {Deborah M.} and Denise Campagnolo and Williams, {James R.} and Fitzgerald, {Kathryn C.} and Kuangnan Xiong and McGinley, {Marisa P.} and Megan Hyland and Rudick, {Richard A.} and Tjalf Ziemssen and Irene Koulinska",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CMH: speaking and consulting fees from Biogen, Genentech, Genzyme, EMD Serono, and Novartis; research support paid to her institution from Biogen, Genentech, and the Patient-Centered Outcomes Research Institute (PCORI); BK, KX, RAR, IK: employees of Biogen at the time of these analyses and may have received stock/stock options in Biogen; CdM, DC, JRW: employees of and may hold stock/stock options in Biogen; DMM: served as a consultant for Roche and has received royalties from the Cleveland Clinic for licensing MSPT-related technology; KCF: funded by a Career Transition Fellowship from the National MS Society (NMSS); MPM: served on scientific advisory boards for Genentech, Genzyme; received research support from Novartis; receives funding from a KL2 (KL2TR002547) grant from Clinical and Translational Science Collaborative of Cleveland, from the National Center for Advancing Translational Sciences (NCATS) component of the NIH; MH: research support paid to her institution from Biogen and PCORI; TZ: personal compensation from Bayer, Biogen, Celgene, Novartis, Roche, Sanofi, and Teva for consulting services; additional financial support for research activities from BAT, Bayer, Biogen, Novartis, Sanofi, and Teva. Publisher Copyright: {\textcopyright} The Author(s) 2021.",
year = "2021",
doi = "10.1177/20552173211004634",
language = "English (US)",
volume = "7",
journal = "Multiple Sclerosis Journal - Experimental, Translational and Clinical",
issn = "2055-2173",
publisher = "SAGE Publications Inc.",
number = "2",
}